drugset / Trial / NCT07654374
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Phase 3
Not yet recruiting
1100 enrolled
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
RandomizedParallel-groupTriple-blindTreatment
Summary
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.
Timeline
- Start
- 2026-07
- Primary completion
- 2028-09
- Completion
- 2028-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aleniglipron | Small molecule | — | Oral |